Helix Biopharma Insider Trading

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, operating in the healthcare biotechnology sector with a focus on immune-oncology. Its primary technology platform centers on L-DOS47, an antibody-enzyme conjugate designed to neutralize the microenvironment of solid tumors. The company has several clinical programs built around this platform, including trials targeting non-small cell lung cancer at various stages and phase Ib/II trials for pancreatic cancer and lung cancer. Helix also develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. The company holds collaboration agreements with Moffitt Cancer Center, focused on studying the pharmacodynamics of L-DOS47 and its potential combination with immune checkpoint inhibitors, and with University Hospital Tuebingen, which is assessing the therapeutic response of L-DOS47 in cancer models expressing CEACAM6 using advanced preclinical metabolic imaging. Additionally, Helix has an agreement with metaShape Pharma AG covering LEUMUNA, a product directed at adipose tissue-related and metabolic diseases. The company was incorporated in 2008.